Management of First‑Degree AV Block with Sinus Bradycardia in Healthy Adults

Clinical Assessment

Asymptomatic individuals with isolated first‑degree AV block and sinus bradycardia do not require treatment; the combination is often physiologic and pacing is not indicated. – American College of Cardiology (ACC) [1]
Key cardiac symptoms to evaluate include exertional intolerance, fatigue, dyspnea, and chest discomfort. – ACC/AHA (Circulation) [2]
Signs of heart‑failure that should be screened for are orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema. – ACC/AHA (Circulation) [2]

A PR interval ≥300 ms may produce “pseudo‑pacemaker syndrome,” characterized by loss of AV synchrony, reduced cardiac output, and elevated pulmonary capillary wedge pressure even with 1:1 conduction; this warrants closer evaluation. – ACC/AHA (Circulation) [2]
Lyme disease serology should be considered when epidemiologically appropriate as a reversible cause of conduction delay. – ACC/AHA (Circulation) [3]
A 12‑lead ECG is essential to assess QRS duration and morphology; the presence of bundle‑branch block may indicate more advanced infranodal disease. – ACC (JACC) [1], ACC (JACC) [4]
Transthoracic echocardiography is reasonable to exclude structural heart disease, cardiomyopathy, or infiltrative processes. – ACC/AHA (Circulation) [3]

PR interval ≥ 300 ms together with exertional symptoms. – ACC/AHA (Circulation) [2]
Presence of bundle‑branch block, suggesting infranodal conduction disease. – ACC/AHA (Circulation) [3]

Permanent pacemaker implantation is reasonable (Class IIa) only when:
No pacing is recommended for asymptomatic patients with isolated first‑degree AV block and sinus bradycardia, as the procedural risks outweigh any potential benefit. – ACC (JACC) [1]

Athletic individuals often exhibit physiologic sinus bradycardia and first‑degree AV block due to heightened vagal tone; no intervention is required unless symptoms develop during de‑conditioning or at rest. – ACC/AHA (Circulation) [3]
Progression risk: In otherwise healthy adults, isolated first‑degree AV block carries a low risk of progression to higher‑grade AV block; however, concurrent bundle‑branch block increases this risk and warrants periodic ECG surveillance. – ACC/AHA (Circulation) [3]

The American College of Cardiology recommends documenting temporal correlation between symptoms and bradycardia using appropriate cardiac monitoring, such as a Holter monitor, event recorder, or implantable cardiac monitor, to establish symptom correlation 5
The American Heart Association suggests looking for symptoms of cerebral hypoperfusion, including syncope, presyncope, transient dizziness, lightheadedness, confusion, or heart failure symptoms, to determine the severity of the condition 6
Asymptomatic patients with sinus bradycardia and a short PR interval require no treatment, as this condition is often physiologic in young individuals, athletes, and during sleep, according to the American College of Cardiology 7

The American College of Cardiology recommends reviewing all negative chronotropic agents, including beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, and antiarrhythmic drugs, to identify potential reversible causes 5
Consider checking thyroid function tests to exclude hypothyroidism, and measure electrolytes, particularly potassium, calcium, and magnesium, to evaluate for metabolic abnormalities 5

The American College of Cardiology states that permanent pacing should not be performed in asymptomatic individuals with sinus bradycardia, even with physiologically elevated parasympathetic tone, due to the risks associated with pacemaker implantation 7
For symptomatic patients with hemodynamic stability, the American Heart Association suggests addressing all reversible causes and considering a trial of oral theophylline to increase heart rate and assess potential benefit of permanent pacing 5
In acute symptomatic patients with hemodynamic compromise, the American College of Cardiology recommends administering atropine 0.5-1 mg IV as first-line treatment, repeated every 3-5 minutes to a maximum total dose of 3 mg, and considering temporary transvenous pacing if medications fail 5

The American College of Cardiology advises against pacing based solely on heart rate below an arbitrary cutoff or pause duration without documented symptom correlation, and avoiding permanent pacing in patients with documented symptoms occurring in the absence of bradycardia 7
The American Heart Association recommends not overlooking reversible causes, particularly medications and metabolic abnormalities, before proceeding to device therapy, and maintaining a higher threshold for permanent pacing in young patients given long-term device implications 5